Astrazeneca (AZN) Change in Working Capital (2009 - 2026)

Astrazeneca (AZN) has reported Change in Working Capital for 18 consecutive years, with $7.5 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Working Capital rose 44.31% year-over-year to $7.5 billion; the TTM figure through Mar 2026 stood at $8.0 billion (up 171.91% YoY), while the FY2025 annual figure was $5.7 billion, up 4.95% from the prior year.
• Change in Working Capital came in at $7.5 billion for Q1 2026 at Astrazeneca, up from -$2.4 billion in the prior quarter.
• The five-year high for Change in Working Capital was $7.7 billion in Q1 2024, with the low at -$3.0 billion in Q2 2022.
• Average Change in Working Capital over 5 years is $2.0 billion, with a median of $1.0 billion recorded in 2025.
• Across the five-year window, Change in Working Capital jumped 459.93% in 2022 and plunged 339.64% in 2025, its largest moves.
• Year by year, Change in Working Capital stood at -$3.0 billion in 2022, then soared by 87.95% to -$357.0 million in 2023, then surged by 378.43% to $994.0 million in 2024, then slumped by 339.64% to -$2.4 billion in 2025, then jumped by 415.45% to $7.5 billion in 2026.
• According to Business Quant data, Change in Working Capital over the past three periods registered $7.5 billion, -$2.4 billion, and $1.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.